Neumora’s major depression drug flunks first of three Phase 3 trialsnews2025-01-02T12:25:26+00:00January 2nd, 2025|Endpoints News|
Roche circles back to China biotech with $80M deal for lung cancer ADCnews2025-01-02T11:39:42+00:00January 2nd, 2025|Endpoints News|
Flagship biotech Valo Health ends 2024 with mid-stage failnews2024-12-31T16:23:52+00:00December 31st, 2024|Endpoints News|
Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesnews2024-12-31T16:09:12+00:00December 31st, 2024|Endpoints News|
Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalnews2024-12-30T15:49:33+00:00December 30th, 2024|Endpoints News|
Next pipeline drugs for weight loss after CagriSema disappointmentnews2024-12-23T16:24:05+00:00December 23rd, 2024|Endpoints News|
Bristol Myers’ TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trialsnews2024-12-23T15:14:04+00:00December 23rd, 2024|Endpoints News|
FDA approves Humacyte’s lab-grown blood vesselsnews2024-12-20T18:53:56+00:00December 20th, 2024|Endpoints News|
GSK’s Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survivalnews2024-12-20T16:37:07+00:00December 20th, 2024|Endpoints News|
Aadi starts from scratch as it sells assets, licenses ADCs and raises new fundsnews2024-12-20T11:58:29+00:00December 20th, 2024|Endpoints News|
